SPRB May 2024 2.500 put
| Previous close | 1.6500 |
| Open | 1.6500 |
| Bid | 1.4500 |
| Ask | 2.0500 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 1.6500 - 1.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksSpruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 12.50% and 79.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireSpruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif., May 13, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates.
Business WireSpruce Biosciences to Participate in May Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 01, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in two upcoming investor conferences taking place in May.
